GBA Presents: RADIO SAVANT-!

Liberty Formula One price target raised to $82 from $70 at Pivotal Research 05:17 FWONK

Folks you will recognize DV above is a GBA stock already and we have been in Formula 1 before and have been looking at it recently.

Another holding we may have to deal with today is our favorite x-Ray machine stock. It may be up in the pre but I never trust these things. This is one of my bigger (by share count holdings)

  • Evolv Technologies Holdings, Inc. (EVLV) up 17.7%
 
-->Evolv reports Q4 adjusted EPS (12c), consensus (14c) » 16:24 EVLV

-->DoubleVerify reports Q4 EPS 25c, consensus 11c » 16:24 DV

Evolv sees FY23 revenue $55M-$60M, consensus $60.14M 16:24 EVLV Sees FY23 adjusted EBITDA ($60M)-($55M).

>> DoubleVerify sees Q1 revenue $117M-$119M, consensus $117.41M 16:24 DV Sees Q1 adjusted EBITDA $28M-$30M.
 
STOCKOF THE DAY - SQ


https://thefly.com/news.php?symbol=SQ#
A) Baird 'wouldn't be surprised' if price hikes add $60M to Square gross profit 15:42
SQ
After Square announced it is raising prices across three products, Baird analyst David Koning said the firm "wouldn't be surprised" if the hikes add at least $60M to Square segment annualized gross profit, which is 2%-plus to segment gross profit and about 1% to total company gross profit. The firm has an Outperform rating and $92 price target on Square parent Block.

ShowRelated Items >>

B) Square provides policy and pricing updates 12:06
SQ
In a blog post, Square said: "Occasionally, Square needs to update policies and pricing for our products to better align to evolving costs from our network and payments partners. In these scenarios, we make pricing changes so that we can invest in our platform, create new features, and continue expanding the value Square provides its sellers. Because we have a growing, multifaceted ecosystem of integrated business and commerce tools, we work carefully across product lines to minimize disruptions and changes. Beginning next month, three new pricing changes are going into effect for Square sellers: updates to our refund policy, changes to paid transfers pricing, and new pricing for our revamped Square Online paid plans. We are updating Square's refund policy so that processing fees will no longer be returned when sellers issue a full or partial refund to their buyers. The fee for instant and same-day transfers is changing from 1.5% to 1.75% per transfer. For ecommerce and omnichannel sellers, we are consolidating the plans we offer for Square Online to 3 distinct tiers - Free, Plus, and Premium - and recalibrating prices across paid plans. For existing sellers in the U.S., the new refund policy and paid transfers pricing will go into effect on April 11, 2023."


At first blush a raise from 1.5% --> 1.75% seems very minimal and I did gloss over this the first time I read it yesterday but on how many transactions> It may very well add up.
 
stonedinvestor said:
21 hOspitalS//// LI Island hospital sOme OTHER HOSPITAL URGENT ALERT URGENT ***********CHANEL 2 NEWS JUST DID A BIG PIECE ON OUR EVOLVE EVLV BUY BUY BUY

SWEEPING NYC I KNEW IT!!!! EVERYONE IS GOING TO WANT ONE... I WANT ONE!!!!

DRINK-! WE HIT IT BOYS!!@#A$WSE%DR^FTGYHUOJIMP<>:"?
More...







Stk was $1.70-$2.00 at this time!!!!!!!

Evolv Technologies Holdings, Inc. (EVLV)
NasdaqCM - NasdaqCM Real Time Price.
2.7100-0.0400(-1.45%)
At close: 04:00PM EST
3.1300+0.42(+15.50%)
After hours:07:58PM EST
 
Former GBA Stock-NTLA

The U.S. Food and Drug Administration (FDA) cleared Intellia Therapeutics' (NASDAQ:NTLA) application seeking to start a trial of CRISPR-based gene editing therapy, NTLA-2002 in the U.S. to treat hereditary angioedema (HAE).

The clearance of the investigational newdrug (IND) the company to include the U.S. in a global phase 2 portion of its ongoing phase 1/2 study.

Intellia noted that NTLA-2002 is an in vivo genome editing therapy aimed to inactivate the target gene kallikrein B1 (KLKB1) to permanently reduce plasma kallikrein protein activity and thereby prevent HAE attacks after a single-dose treatment.

HAE is a disorder characterized by recurrent episodes (attacks) of severe swelling of the skin and mucous membranes.

"We are thrilled to advance the development of NTLA-2002 in the U.S. and are working to rapidly enroll patients in the Phase 2 portion of the study. We look forward to presenting additional data from the first-in-human, Phase 1 portion of the study later this year,"saidIntellia's President and CEO John Leonard.

The company hadreportedinitial data from the phase 1/2 trial in September 2022.

Intellia noted that the phase 2 portion of the study recently began patient screening outside the U.S.

NTLA+9.01%to $44.42 premarket March 3
 
stonedinvestor said:
Liberty Formula One price target raised to $82 from $70 at Pivotal Research 05:17 FWONK

Folks you will recognize DV above is a GBA stock already and we have been in Formula 1 before and have been looking at it recently.

Another holding we may have to deal with today is our favorite x-Ray machine stock. It may be up in the pre but I never trust these things. This is one of my bigger (by share count holdings)

  • Evolv Technologies Holdings, Inc. (EVLV) up 17.7%
More...
Did my quick once over of DV... I doubt it'll close above $28.
It's gonna drop too.
Priced beyond perfection.

The best hope today is for PSTG.
They were the most solid of any report last night.
You're welcome btw.
I put a lot of work into that one.
 
vanzandt said:
PSTG>>> $25.70
Buy it.
More...



Good morning VZ!! Did you get my PSTG info?

I tried to create one of those BULL/ Bear Spreads you taught me I had a good feeling they were going to miss. I had some trouble figuring it out and ran out of time. -- Thought there was a trade for you there yesterday.
 
You must log in or register to reply here.
Back
Top